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Background: HDAC6 plays an important role in cell migration.
Results: ERK interacts with and phosphorylates HDAC6 to promote cell migration.
Conclusion: ERK signaling pathway promotes cell migration, in part, through phosphorylating HDAC6.
Significance: Inhibition of HDAC6 activity as well as the EGFR-Ras-Raf-MEK-ERK signaling pathway may cooperatively
reduce cell migration.
Histone deacetylase 6 (HDAC6) is well known for its ability to
promote cellmigration through deacetylation of its cytoplasmic
substrates such as-tubulin.However, howHDAC6 itself is reg-
ulated to control cell motility remains elusive. Previous studies
have shown that one third of extracellular signal-regulated
kinase (ERK) is associated with the microtubule cytoskeleton in
cells. Yet, no connection between HDAC6 and ERK has been
discovered. Here, for the first time, we reveal that ERK binds to
and phosphorylates HDAC6 to promote cell migration via
deacetylation of -tubulin. We have identified two novel ERK-
mediatedphosphorylation sites: threonine1031 and serine 1035
in HDAC6. Both sites were phosphorylated by ERK1 in vitro,
whereas Ser-1035was phosphorylated in response to the activa-
tion of EGFR-Ras-Raf-MEK-ERK signaling pathway in vivo.
HDAC6-null mouse embryonic fibroblasts rescued by the non-
phosphorylation mimicking mutant displayed significantly
reduced cell migration comparedwith those rescued by the wild
type. Consistently, the nonphosphorylation mimicking mutant
exerted lower tubulin deacetylase activity in vivo comparedwith
the wild type. These data indicate that ERK/HDAC6-mediated
cell motility is through deacetylation of -tubulin. Overall, our
results suggest that HDAC6-mediated cell migration could be
governed by EGFR-Ras-Raf-MEK-ERK signaling.
Histone acetyltransferases and histone deacetylases (HDACs)3
are enzymes involved in modifying core histones through the
addition or removal of an acetyl group from the lysine residue
on histone tails. Acetylation of core histones usually results in
transcriptional activation, whereas deacetylation of core his-
tones causes transcriptional repression (1, 2). Apart from his-
tones, it is well known that HDACs also modify nonhistone
proteins which in turn regulate the functionality of those pro-
teins (3). HDACs are grouped into four classes based on their
similarity to yeast homologs and the usage of cofactors. They
are class I (HDACs 1, 2, 3, and 8), class II (HDACs 4, 5, 6, 7, 9,
and 10), class IV (only HDAC11), and the silent information
regulator 2 (sir2)-related family which represents the class III
HDACs consisting of sirtuins 1–7 (1, 2, 4). The classes I, II, and
IV of HDACs require Zn2 to be active, whereas the class III
HDACsbearing no sequence similarity to class I, II, and IVneed
NAD as a cofactor (2). The class I HDACs are ubiquitously
expressed inmany cell types and are found almost exclusively in
the nucleus. However, the expression pattern of class II HDACs
is more restricted, and they are able to shuttle between the
nucleus and the cytoplasm in response to cellular signals (1,
5–7). HDAC6 which belongs to the class II HDACs is unique
among HDACs in that it is the only HDAC that contains a
complete duplication of the large class I/II HDAC homology
domain. HDAC6 consists of both a nuclear export signal
located in the N terminus and a cytoplasmic anchorage motif
known as SE-14 motif in the C terminus (8, 9) and a zinc finger
motif, which binds to mono- and polyubiquitin chains (9, 10).
HDAC6 is recognized for deacetylating cytoplasmic proteins,
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including -tubulin (11, 12), cortactin (13), and HSP90 (14).
HDAC6 associates with microtubules through its HDAC
domain and is capable of deacetylating -tubulin at lysine 40
both in vivo and in vitro (12). It is generally believed that
deacetylation of microtubules and cortactin by HDAC6 influ-
ences microtubule-dependent and actin-dependent cell motil-
ity, respectively (11, 13).
Recently, phosphorylation sites within HDAC6 as well as
kinases that are responsible for phosphorylating these sites
have started to emerge. For instance, glycogen synthase kinase
3has been reported to phosphorylate the serine 22 site located
in the N terminus of HDAC6 (15). It has been suggested that
glycogen synthase kinase 3 enhances HDAC6 deacetylase
activity toward -tubulin (15). HDAC6 can also be phosphory-
lated by Aurora A kinase, a centrosomal kinase involved in reg-
ulating mitotic entry (16). Phosphorylation of HDAC6 by
Aurora A enhances the ability of HDAC6 to deacetylate acety-
lated -tubulin to promote ciliary disassembly, but the phos-
phorylation site for this kinase remains to be identified (16).
Recently, theG protein-coupled receptor kinase 2 has also been
shown to phosphorylate HDAC6 and stimulate its -tubulin
deacetylase activity (17). In addition to -tubulin, phosphory-
lation of HDAC6 also alters its deacetylase activity toward other
substrates, such as -catenin. As reported by Zhu et al., protein
kinase C  (PKC) enhances HDAC6 deacetylase activity
toward -catenin and regulates its nuclear translocation and
promoter binding (18). Besides serine/threonine kinases, tyro-
sine kinases such as epidermal growth factor receptor (EGFR)
kinase have been shown to phosphorylate tyrosine 570 within
the HDAC6 C-terminal deacetylase domain, which results in a
decrease in the deacetylase activity of HDAC6, an increase in
-tubulin acetylation, and an altered EGFR trafficking (19).
Overall, numerous kinases could targetHDAC6and regulate its
activity toward its substrate and ultimately influence cell motil-
ity or other cellular functions.
Extracellular signal-regulated kinase 1 and 2 (ERK1/2) are
related protein-serine/threonine kinases that participate in the
EGFR-Ras-Raf-MEK-ERK signal transduction cascade (20).
Downstream targets of ERK1/2 are involved in many biological
processes including cell migration. Migration of cells is shown
to be influenced by ERK because inhibition of ERK by MEK
inhibitor U0126 or PD98059 reduces cell migration in various
cell types (21). It is believed that ERK regulates cellmigration by
targeting its nuclear or cytoplasmic substrates. One such ERK
target is a nuclear protein, ELK-1, that is a member of the ter-
nary complex factor subfamily of Ets (E-twenty six)-domain
transcription factors. ELK-1 phosphorylation leads to pro-
longed c-Fos expression and results in increased expression of
several genes including matrix metalloproteinase-9 (MMP-9),
which promotes cell motility (22). ERK can also promote cell
migration on extracellular matrix in a transcription-indepen-
dent manner by directly impacting the migratory machinery in
the cytosol. This occurs by enhancing the activity of myosin
light chain kinase, which leads to increased myosin light chain
phosphorylation and enhanced migration (23). Moreover, ERK
has been shown to be associated with the microtubules (24).
Here we have identified a novel ERK substrate, HDAC6. Our
studies have suggested that phosphorylation of HDAC6 is
important for EGFR-Ras-Raf-MEK-ERK cascade-mediated cell
motility.
EXPERIMENTAL PROCEDURES
Plasmids, Antibodies, Reagents, and Cell Lines—HA-HD6-F
is described inRef. 13.HA refers to a hemagglutinin tag. F refers
to the FLAG peptide. The point mutations on this construct
were created by QuikChange XL Site-directed Mutagenesis
kit (Stratagene). For HA-HD6(S1035A)-F, the primers used
were 5-CCACCAGACCCCCCCAACCGCACCTGTGCAG-3
and 5-CTGCACAGGTGCGGTTGGGGGGGTCTGGTGG-3.
For HA-HD6(S1035D)-F, the primers used were 5-CCACCAG-
ACCCCCCCAACCGACCCTGTGCAG-3 and 5-CTGCACA-
GGGTCGGTTGGGGGGGTCTGGTGG-3. GST-HD6(816–
1215) plasmid was constructed by inserting the PCR-amplified
HDAC6 sequence derived from HA-HD6-F into the SalI/NotI
sites of pGEX-4T1 vector using the following primers: SalI/
HDAC6, 5-AGTCGACGGGCCCTGGCCTCAATCACTG-3
andNotI/HDAC6, 5-AGCGGCCGCTTAGTGTGGGTGGGG-
CATATCC-3. Pointmutations ofHDAC6 in this construct were
created using the following primers: for GST-HD6(816–
1215)S1045A, 5-CACCCCAGATAGCTCCCAGTACACTGA-
TTG-3 and 5-CAATCAGTGTACTGGGAGCTATCTGGGG-





GCCTGGTGG-3; for GST-HD6(816–1215)S1035A, the prim-
ers are the same as used for generation of HA-HD6(S1035A)-F.
ThePCRcyclewas as follows: 95 °C, 1min; followedby 95 °C, 50 s;
60 °C, 50 s; 68 °C, 20min for 25 cycles; and then 68 °C, 30min.The
GST-HD6, GST-HD6(1–503), GST-HD6(448–840), and GST-
HD6(840–1215) plasmidswere generated by inserting PCRprod-
ucts into pGEX-4T-1 vector. Detailed information is available
upon request. The pLEX-GST-DN-ERK1 plasmid was made as
follows. The human wild type ERK1 cDNA was isolated from
pDONR223-MAPK3(AddgenePlasmid23509)vectorbyPCRand
then subcloned intopGEXtogeneratepGEX-ERK1.The resulting
plasmid was then used as a template to generate dominant nega-
tive (DN) ERK1(T202A/Y204F) using the following primers: for-
ward, 5-GACCACACCGGCTTCCTGGCCGAGTTTGTGGC-
TACGCGCTGGTAC-3 and reverse, 5-CAGGAAGCCGGTG-
TGGTCATGCTCAGG-3. The mammalian expression vector
pLEX-GST-DN-ERK1 was made by inserting the digested GST-
DN-ERK1 between SpeI and XhoI sites in pLEX-MCS vector
(Open Biosystem). C-RAF-BXB was described in Ref. 25;
HA-Ras(G12V), HA-MEK(K97A), and HA-MEK(S218/222D)
werekindgifts fromDr. JieWu.EGFR(vIII)plasmidwasdescribed
by Shen et al. (26). pEF-BOS-GST-Braf(V600E) mammalian
expression vector was a kind gift fromDr. ChuanguiWang.
Anti-HDAC6(H300) and anti-EGFR(1005) antibodies were
purchased from Santa Cruz Biotechnology. Anti-phosphoser-
ine/threonine antibody was purchased from BD Biosciences.
Anti-HA antibody was purchased from Covance. Anti-acety-
lated -tubulin antibody, anti--tubulin antibody, and Lipo-
fectamine 2000 reagent were purchased from Invitrogen. Anti-
FLAG antibody, collagen I (C7661), shRNA vectors against
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ERK1 (TRCN0000006150) and ERK2 (TRCN0000010040)
were purchased from Sigma. Anti-ERK1/2 antibody (9102),
anti-phospho-ERK1/2 (Thr-202/Tyr-204) antibody (9101), anti-
phospho-MEK1/2 (Ser-217/Ser-221) antibody (9121), anti-
GST (91G1) antibody (2625), anti-MEK1/2 antibody (9122),
recombinant ERK1 kinase (7416), and human EGF (8916SC)
were purchased from Cell Signaling. U0126 and PD98059 were
purchased from Calbiochem. Phosphorylated HDAC6 Ser-
1035-specific polyclonal antibody, anti-pSer-1035(HDAC6),
was produced by immunizing rabbits with keyhole limpet
hemocyanin-conjugated peptide: DHQTPPT(pS)PVQG. The
antibody was purified by phospho-peptide affinity column.
CHO, a Chinese hamster ovary cell line, H1299, andHDAC6
wild type and knock-out mouse embryonic fibroblasts (MEFs),
293T, andHeLa S3 cellswere cultured inDMEMwith penicillin
(100 units/ml), streptomycin (100 g/ml), and 10% fetal bovine
serum (FBS) and incubated at 37 °C with 5% CO2. HeLa S3
suspension cells were cultured in Joklik medium (Sigma).
Generation of Baculoviruses—The baculoviruses expressing
F-HD6, F-HD6(S1035A), and F-HD6(S1035D) were generated
from modified pFastBac-HTb donor vector (Invitrogen) in
which the His tag was changed to a FLAG tag. The bacmids
containing the above cDNAs were generated by transposition
in Escherichia coli cells according to the manual of Bac-to-Bac
system (Invitrogen). Baculoviruses expressing wild type and A
or D mutant of HDAC6 proteins were generated by transfec-
tion of recombinant bacmids into Sf9 cells using CellfectinII
Reagent (Invitrogen). The P2 stocks of baculoviruswere used to
infect Sf9 cells. The overexpressed F-HD6, F-HD6(S1035A),
and F-HD6(S1035D) in Sf9 cells were purified using anti-FLAG
M2 agarose (Sigma). GST-HDAC6 baculoviruses were made as
follows. HDAC6 was first inserted between SalI and NotI sites
after a GST tag in pGEX-4T1 vector. Then GST-HDAC6 was
amplified by PCR and inserted between SpeI and HindIII in
pFastBac-1 vector (Invitrogen). The bacmid for GST-HDAC6
was made and used for baculovirus production followed by
GST-HDAC6 protein expression and purification.
In Vitro Kinase Assay—GST fusion proteins containing C
terminus of wild type or mutant of HDAC6 as shown in Fig. 2A
were incubated with recombinant ERK1 (Cell Signaling) in the
presence of 5 Ci of [-32P]ATP, 10 M ATP, and 1 kinase
buffer (10mMTris, pH 7.4, 150mMNaCl,10mMMgCl2, 0.5mM
dithiothreitol (DTT)) for 30 min at 30 °C. Reactions were ter-
minated by adding SDS loading buffer followed by heating at
100 °C for 5min. Proteinswere separated on 6%SDS-polyacryl-
amide gel, and the phosphorylated proteins were visualized by
autoradiography.
Immunoprecipitation and Immunoblotting—For immuno-
precipitations, cells were lysed in LS buffer (PBS, pH 7.5, 10%
glycerol, 0.1% Nonidet P-40, and protease inhibitor mixture).
Lysates were incubated with protein A- or protein G-agarose
for 2 h for preclearing prior to incubation with the indicated
primary antibodies for 12 h at 4 °C. Immunocomplexes were
collected, washed four times in lysis buffer, and resolved by
SDS-PAGE. For immunoblotting, samples were transferred to
nitrocellulose membranes that were then probed with the indi-
cated antibodies. Bound antibodies were detected using a
Chemiluminescent Detection kit (Pierce).
HDAC Assay—Empty vector, HA-HD6-F, HA-HD6(S1035A)-
F, or HA-HD6(S1035D)-F protein purified from 293T trans-
fected cells lysate was precleared with protein A beads and
immunoprecipitated with anti-FLAG beads before protein
deacetylase activity was determined. Briefly, [3H]acetate-incor-
porated histones were isolated from butyrate-treated HeLa
cells by acid extraction as described in Ref. 27. Purified core
histones (12,000 cpm) were incubated with immunoprecipi-
tates in 150 l of ice-cold histone deacetylase buffer (20 mM
Tris, pH 8.0, 150 mM NaCl, and 10% glycerol) at 37 °C for 2 h.
The reactionwas terminatedby the additionof anequal volumeof
stop solution (0.16 M acetic acid, 1.0 M HCl) and mixed well by
vortexing. The released [3H]acetate was extracted with ethyl ace-
tate and combined with scintillation mixture for analysis. Addi-
tionally, HDAC6 and itsmutants (S1035A and S1035D) were also
obtained from Sf9 insect cells. The purified proteins were used to
performedHDAC assay as was done with 293T cells.
Tubulin Deacetylase (TDAC) Assay—Briefly, proteins were
incubated with 100 l of 2 TDAC buffer (20 mM Tris-Cl, pH
8.0, 20 mM NaCl) and 50 g of reconstituted microtubules
(Cytoskeleton) in a 200-l reaction at 37 °C for 2 h, then trans-
ferred to ice for 15 min. A fraction of the reactions were ana-
lyzed by Coomassie staining or Western blot analysis using
anti--tubulin and anti-acetylated -tubulin antibodies.
Establishment of Stable Clones—To generate the rescue
clones in HDAC6 knock-out MEFs, empty vector, HA-HD6-F,
HA-HD6(S1035A)-F, and HA-HD6(S1035D)-F were trans-
fected into HDAC6 knock-out MEFs using Lipofectamine Plus
reagent. One day after transfection, 500g/ml G418 was added
to the medium to select positive cells. Ten days later, stable cell
lines were subcloned to 60-mm dishes, and 300 g/ml G418
was added to maintain the stable clones. The generated stable
clones were used in migration experiments.
Cell Migration Assay—First, 24-well Transwell migratory
cell inserts (8-m pores, Fisher Scientific) were coated with 5
g of collagen 1 and incubated at 4 °C overnight. Before use,
liquid was aspirated out, and the insertswere rinsedwith PBS and
allowedtodry insterile condition.Total4104cells in serum-free
mediumwere seeded into inserts in duplicates. 500 l of medium
with 10% FBS was added to the bottom of the well and served as
attractant. Cells were allowed to migrate through the inserts for
24 h at 37 °C. Cells that did not migrate were removed with a
cotton swab, and migratory cells were fixed with 4% paraformal-
dehyde and stained with crystal violet in ethanol. Snapshots were
taken of the migratory cells, and then cells were destained in 2%
SDS, and absorbances were read at 560 nm.
Statistical Analysis—Results obtained from independent
studies are shown with mean  S.D. Statistical analysis was
performed using Student’s t test. A p value  0.05 was consid-
ered significant.
RESULTS
Thr-1031 and Ser-1035 of HDAC6 Are Phosphorylated by
ERK1 in Vitro—To identify novel phosphorylation sites in HDAC6,
293T cells were transduced with adenovirus HA-HD6-F (13)
for 36 h. The cells were then lysed, and HDAC6 was immuno-
precipitated by anti-FLAG antibodies. The immunoprecipi-
tates were resolved on SDS-PAGE followed by Coomassie Blue
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FIGURE 1. Thr-1031 and Ser-1035 are phosphorylated in HDAC6. A and B, the peptide was detected at 32.6 min in the total ion chromatogram (TIC) (A) with
mass-to-charge ratio 1068.5189, triply charged, which represents an error of 6.8 ppm (B). C, the tandem mass spectrum (MS/MS) matched the following
sequence, HQTPPTSPVQGTTPQISPSTLIGSLRTLE, indicating that Thr-1031 and Ser-1035 (highlighted in red) were phosphorylated; the detection of b3, y22, and
y23 is consistent with this localization. The assignment was made with Mascot with a score of 50 and Sequest XCorr 5.62. D, ion chromatograms for peptides
containing both phosphorylated Ser-1035 and unmodified Ser-1035 were extracted using Xcalibur 2.0 (Thermo Scientific). The peak areas under the curves
were used to calculate the percentage of phosphorylation. E, upper panel, the consensus ERK1/ERK2 recognition motif is shown. Lower panel, a stretch of HDAC6
amino acid sequence showing the conservation of mass spectrometry analyses identified two ERK1/ERK2 sites (Thr-1031 and Ser-1035) and a putative
ERK1/ERK2 site (Ser-1045) among rat, mouse, dog, and human.
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staining. HDAC6 band was excised and subjected to LC-tan-
demMS analyses. As shown in Fig. 1,A–C, the mass spectrom-
etry analyses identified two novel phosphorylation sites located
in the C-terminal region of HDAC6, namely threonine 1031
and serine 1035. The extent of HDAC6 phosphorylation on
these two sites was also examined by quantitative mass spec-
trometry. The majority of immunoprecipitated wild type
HDAC6 (82.5%) was phosphorylated (Fig. 1D), suggesting the
importance of Thr-1031 and Ser-1035 sites. Between these two
sites, Ser-1035 is within the ERK consensus motif (P-X-S/T-P)
(28), whereas Thr-1031 is not (Fig. 1E). In addition, Thr-1031
and Ser-1035 were conserved among rat, mouse, dog, and
human but not Drosophila and fish (Fig. 1E and data not
shown), suggesting that these sites are conserved in mammals.
Although Ser-1045 is also located within an ERK motif, the
mass spectrometry analyses did not reveal it as a phosphoryla-
tion site. Based on this information, we set out to determine
whether ERK is indeed involved in phosphorylating these sites.
To this end, we used recombinant ERK1 and the C-terminal
fragments of HDAC6 harboring wild type ormutants (T1031A,
S1035A,T1031A/S1035A, S1045A) (Fig. 2A) to perform in vitro
kinase assays. Our results showed that Ser-1035 was a major
phosphorylation site for ERK1 as evidenced by the disappear-
ance of the phosphorylation signal when this site was mutated
FIGURE 2. HDAC6 is phosphorylated by ERK1 in vitro at Thr-1031 and Ser-1035. A, diagrams show full-length and C terminus of HDAC6 with putative
phosphorylation sites. B, upper panel, in vitro kinase assays were performed with the indicated substrates and recombinant ERK1 as described under “Experi-
mental Procedures.” The reactions were separated on 6% SDS-PAGE and analyzed by autoradiography. Lower panel, Coomassie Blue staining of the substrates
shows the protein amount and purity for kinase assays.
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from serine to alanine (Fig. 2B, lane 3). Although the Thr-1031
site was mutated to alanine, there was a moderate decrease in
the levels of phosphorylation (Fig. 2B, lane 4 versus lane 2),
indicating that theThr-1031 site is not amajor ERK1phosphor-
ylation site. The results also showed that phosphorylation of
Thr-1031 by ERK1 was dependent on Ser-1035 phosphoryla-
tion because in the double mutant, HD6(816–1215)T1031A/
S1035A, no phosphorylation signal was observed (Fig. 2B, lane
5). Moreover, the phosphorylation signal of S1045A was com-
parable with that of the WT (Fig. 2B, lane 6 versus lane 2),
showing that Ser-1045 was not phosphorylated by ERK1 in
vitro. In addition, we also examined whether another MAPK,
p38, can phosphorylate theC-terminal region ofHDAC6.Our
analyses showed that the p38 kinase phosphorylated wild type
as well as T1031A, S1035A, and S1045Amutants of HDAC6 to
a similar extent, suggesting that Thr-1031, Ser-1035, and Ser-
1045 are not p38 phosphorylation sites (data not shown). Col-
lectively, the mass spectrometry analyses and in vitro kinase
assays have demonstrated that Ser-1035 and Thr-1031 can be
phosphorylated by ERK1 in vitro, whereas Ser-1045 cannot.
Ser-1035 of HDAC6 Is Phosphorylated through EGF-EGFR-
Ras-Raf-MEK-ERK Pathway in Vivo—To examine HDAC6
Ser-1035 phosphorylation,we raised the antibody against phos-
phorylated Ser-1035 of HDAC6, anti-pSer-1035(HDAC6) as
described under “Experimental Procedures.” We then further
characterized the antibody. As shown in Fig. 3A, this antibody
only detects phosphorylated HDAC6 protein (lane 1) but not
the one treated with the phosphatase (lane 2). As shown in Fig.
3B, this antibody only recognizes HDAC6wild type (lane 2) but
notHDAC6(S1035A)mutant (lane 3), suggesting that this anti-
body selectively detects phosphorylated Ser-1035 of HDAC6.
Because it was determined that ERK1was a kinase that phos-
phorylated HDAC6 in vitro, we next asked whether phosphor-
ylation by ERK1 also occurred in vivo. MEFs were treated with
the MEK inhibitor U0126 or PD98059, and immunoprecipi-
tation experiments using phosphoserine/threonine antibod-
ies were performed to assess the phosphorylation status of
HDAC6. Compared with the control, both U0126 (10 M) and
PD98059 (100 M) caused a significant decrease in phosphory-
lation ofHDAC6whenERKwas inhibited (Fig. 4A, lane 1 versus
lanes 2 and 3; bar graph). To validate our results, active Ras was
employed to stimulate the Raf-MEK-ERK signaling cascade to
examine whether Ras is able to increase HDAC6 phosphoryla-
tion. Then DN-MEK, HA-MEK(K97A), or DN-ERK1, GST-
DN-ERK1, was transfected into cells to block the MAPK path-
way. As shown in Fig. 4B, active Ras dramatically increased
HDAC6 phosphorylation (lane 3 versus 2), whereas either DN-
MEK or GST-DN-ERK1 significantly decreased HDAC6 phos-
phorylation (compare lanes 4 and 5 with lane 3). The above
results indicate that ERK is indeed involved in promoting phos-
phorylation of HDAC6 in vivo.
We next examined whether HDAC6 Ser-1035 phosphoryla-
tion is increased by upstream kinases of ERK. Active EGFR,
EGFR(vIII), active Ras, Ras(G12V), active Raf, Braf(V600E), and
c-RAF-BXB, and active MEK, MEK(S218/222D) (25, 29) were
transfected into 293T cells to activate endogenous ERK. As
shown in Fig. 4C, all active kinases increased the phosphoryla-
tion levels of HDAC6 wild type but not HDAC6(S1035A)
mutant (Fig. 4C, compare lane 1 with lanes 2, 4, 6, and 8; com-
pare lane 1 with lanes 3, 5, 7, and 9). Therefore, the HDAC6
Ser-1035 site is indeed phosphorylated by the EGFR-Ras-Raf-
MEK-ERK signaling pathway in vivo. Both mass spectrometry
analysis (Fig. 1D) and in vitro kinase assay (Fig. 2) indicate that
Ser-1035 of HDAC6 is a predominant site targeted by ERK.
Consistent with this assumption, the HDAC6(S1035A) or
HDAC6(S1035D) mutant exhibits undetectable levels of phos-
phorylation in cells overexpressing active RAF, c-RAF-BXB
(data not shown).
EGF is one of the ligands for EGFR. We next asked whether
EGF-stimulated EGFR activation could lead to HDAC6 Ser-
FIGURE 3. Characterization of anti-pSer-1035 (HDAC6) antibody. A, anti-
FLAG-M2 bead-purified FLAG-HDAC6 protein from 293T cells was treated
without (lane 1) or with (lane 2) calf-intestinal alkaline phosphatase (CIP) (30
units) (Takara) at 37 °C for 1.5 h. Western blot analysis (IB) was performed with
anti-pSer-1035(HDAC6) antibodies (upper panel). The blot was stripped and
reprobed with anti-FLAG antibodies (lower panel). B, ectopically expressed
5-g empty vector, FLAG-HDAC6 wild type, or S1035A was immunopre-
cipitated (IP) from 293T cells with anti-FLAG-M2 beads. Western blot anal-
ysis was carried out using rabbit anti-pSer-1035(HDAC6) antibodies (upper
panel). The blot was then stripped and reprobed with anti-FLAG antibod-
ies (lower panel).
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FIGURE 4. HDAC6(Ser-1035) phosphorylation is targeted by ERK pathway in vivo. A, HDAC6 phosphorylation is decreased by MEK inhibitor treatment.
MEFs were treated with MEK inhibitor U0126 or PD98059 with the indicated concentration for 1 h. Endogenous HDAC6 was immunoprecipitated (IP) by
anti-HDAC6 antibodies, and the phosphorylation status of HDAC6 was measured by immunoblotting (IB) using anti-phosphoserine/threonine antibodies. The
blot was then stripped and reprobed with anti-HDAC6 antibodies. Anti-pERK and anti-ERK Western blotting analyses were also performed as indicated. The
bands of pHDAC6 were quantified by densitometry and are shown in the bar graph. Student’s t test was performed with * indicating p  0.05. Error bars, S.D.
B, Ras-induced HDAC6 phosphorylation is attenuated by dominant negative MEK and ERK. 293T cells were transfected with the indicated plasmids. HA and
FLAG double-tagged HDAC6 was immunoprecipitated by anti-HA-agarose beads, and phosphorylation of HDAC6 was examined by immunoblotting with
anti-phosphoserine/Thr antibodies. The membrane was then stripped and reblotted with anti-HA antibodies to detect the immunoprecipitation efficiency of
HDAC6, HA-MEK(K97A), and HA-Ras(G12V). The expression of GST-DN-ERK1 was examined by anti-ERK Western blotting. Anti-pERK, anti-ERK, and anti--
tubulin Western blotting analyses were also performed. C, Ser-1035 site is a major phosphorylation site of HDAC6 targeted by the EGFR-Ras-Raf-MEK-ERK
signaling pathway. 293T cells were transiently transfected with the indicated plasmids. Following transfection, cell lysate was immunoprecipitated using
anti-FLAG M2 beads, and the phosphorylation status of HDAC6 (pHDAC6) was determined with anti-pSer-1035 (HDAC6) Western blotting analysis. The blot
was then stripped and reprobed with anti-FLAG antibody to examine the immunoprecipitation efficiency. The levels of EGFR, HA-Ras(G12V), GST-Braf(V600E),
and HA-MEK(S218/222D) were examined by Western blotting analyses using the indicated antibodies. The anti--tubulin Western blotting analyses were also
carried out.
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1035 phosphorylation which is mediated by ERK. As shown in
Fig. 5A, phosphorylation of wild type but not S1035A mutant of
HDAC6 was dramatically increased upon EGF stimulation. EGF-
mediated HDAC6 Ser-1035 phosphorylation was diminished
either by MEK inhibitor, U0126 (Fig. 5B) or DN-ERK1(Fig. 5C),
suggesting thatEGF-mediatedHDAC6Ser-1035phosphorylation
is via ERK1.
Some kinases and their substrates are known to interact. For
example, G protein-coupled receptor kinase 2 binds to and
phosphorylates HDAC6 (17). To determine whetherHDAC6 is
associated with ERK, control anti-IgG, anti-HDAC6 antibody,
bacterial expressed GST-tagged full-length or deletions of
HDAC6 were used to pull down endogenous ERK1/2 in HeLa
S3 nuclear and cytoplasmic fractions which were prepared as
described by Dignam et al. (30). As shown in Fig. 6A, endoge-
nous HDAC6 and ERK1/2 interact in both the nuclear and
cytoplasmic fractions. In addition, HDAC6(1–503) and
HDAC6(448–840) but not HDAC6(840–1215) interact with
FIGURE 5. EGF promotes HDAC6(Ser-1035) phosphorylation via ERK1. A, EGF promotes HDAC6 Ser-1035 phosphorylation. 293T cells were transfected with
indicated plasmids then serum-starved overnight followed by EGF treatment prior to harvest. Wild type or mutant HDAC6 was immunoprecipitated (IP) by
anti-HA antibodies followed by anti-pSer/Thr Western blotting (IB) analyses. The blot was then stripped and reprobed by anti-HA antibodies. The total cell
lysates were also subjected to anti-pERK, anti-ERK and anti--tubulin Western blotting analyses. B, HeLa cells were serum-starved for 24 h followed by
pretreatment with vehicle or 10 M U0126 for 1 h prior to EGF treatment. The Western blotting analyses were performed with the indicated antibodies. C, 293T
cells were transfected with the indicated plasmids. The cells were serum-starved for 24 h followed by 10-min EGF treatment prior to harvest. The Western
blotting analyses were performed with the indicated antibodies.
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ERK1/2 (Fig. 6, B and C), suggesting that ERK1/2 could bind to
HDAC6 N-terminal catalytic domain 1 (DAC1) or domain 2
(DAC2) independently.
Mutation of HDAC6 at Ser-1035 Does Not Affect HDAC6
Histone Deacetylase Activity in Vitro—Histones are known
substrates of HDACs. Therefore, we set out to determine
whether HDAC6 phosphorylation at Ser-1035 is capable of
affecting its deacetylase activity toward core histones. The Ser-
1035 site of HDAC6 was mutated to alanine or aspartic acid to
mimic unphosphorylated or phosphorylated forms of HDAC6,
respectively. Empty vector, wild type, S1035A, or S1035D
mutant was transfected into 293T cells. Wild type and mutant
HDAC6 proteins were immunoprecipitated by anti-FLAG M2
agarose beads and subjected to HDAC assays as described
under “Experimental Procedures.” As shown in Fig. 7A, S1035A
or S1035Dmutation of HDAC6 did not significantly change its
enzymatic activity toward core histones compared with wild
type. Additionally, wild type, S1035A, or S1035D mutant was
also purified from Sf9 cells and subjected to HDAC assays. As
presented in Fig. 7B, both S1035A and S1035D mutants exhib-
ited enzymatic activities comparable with the wild type toward
core histone. The expression of wild type and mutants of
HDAC6 in 293T or Sf9 cells was approximately equal as evi-
denced byCoomassie Blue staining (Fig. 7,A andB). To validate
whether the HDAC6(S1035D) mutant can faithfully mimic
phosphorylation status, HA-HDAC6-F was either transfected
alone or together with active Ras. HDAC6 was immunprecipi-
tated using anti-HA-agarose beads and then subjected to
HDAC assay. As shown in Fig. 7C. HDAC activity was not sig-
nificantly increased when compared with Ras-phosphorylated
FIGURE 6. ERK1/2 interacts with HDAC6. A, HeLa S3 cells were fractionated into nuclear and cytoplasmic fractions as described by Dignam et al. (30).
Immunoprecipitation (IP) was performed using control (anti-IgG) or anti-HDAC6 antibodies followed by anti-ERK and anti-HDAC6 Western blotting analyses.
B, diagrams show HDAC6 full-length and HDAC6 deletion constructs. C, GST beads or GST bead-bound proteins generated from B were incubated with HeLa
S3 nuclear or cytoplasmic fraction, and GST pulldown assays were performed followed by anti-ERK1/2 Western blotting (IB) analyses. Protein expression is
indicated by Coomassie Blue staining.
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HDAC6 and control HDAC6. In addition, we used the recom-
binant ERK1 to phosphorylate HDAC6 proteins purified from
Sf9 cells. As expected, ERK1 increased HDAC6 phosphoryl-
ation dramatically, but HDAC6 enzymatic activity toward
core histone was not significantly elevated compared with
the control HDAC6 (Fig. 7D). Overall, the above results sug-
gest that phosphorylation/unphosphorylation of HDAC6 at
Ser-1035 does not influence its deacetylase activity toward
core histones.
HDAC6(S1035A)Mutant Displays Decreased TDACActivity
Compared with the Wild Type in Vivo—-Tubulin is a known
cytoplasmic substrate of HDAC6 (11). To determine whether
the phosphorylation status ofHDAC6 at its Ser-1035 sitewould
affect its deacetylase activity toward -tubulin, wild type
HDAC6 or its mutant S1035A was transfected into CHO or
H1299 cells. As shown in Fig. 8A, HDAC6(S1035A)-transfected
cells possess higher levels of acetylated tubulin, suggesting that
it harbors lower TDAC activity compared with the wild type.
FIGURE 7. Substitution of Ser-1035 to alanine or aspartate does not affect HDAC6 enzymatic activity toward core histones. A, 293T cells were
transiently transfected with the plasmids as indicated. HDAC6 wild type or mutant complexes were immunoprecipitated by anti-FLAG M2 agarose
beads and then subjected to HDAC assay as described under “Experimental Procedures.” The purified HDAC6 wild type or mutant complexes used in the
HDAC assays are also shown by Coomassie Blue staining. NS, not significant. B, Sf9 cells were transduced by the indicated viruses. HDAC6 wild type or
mutant proteins were purified by anti-FLAG M2 agarose and then subjected to HDAC assays as in A. The purified HDAC6 wild type or mutant proteins
used in the HDAC assays are also shown by Coomassie Blue staining. Data shown are representative of at least three repeated experiments. NS stands
for not significant. C, 293T cells were transiently transfected with HA-HD6-F alone or HA-HD6-F and HA-Ras(G12V). Anti-HA immunoprecipitated (IP)
samples were subjected to HDAC assay as described in A. The phosphorylation status of HDAC6 was examined by anti-HA immunoprecipitation
followed by anti-pSer/Thr Western blotting (IB) analyses. The expression of HA-HD6-F and HA-Ras(G12V) was also examined by anti-HA Western blotting
analyses. D, GST-HD6 proteins were purified from Sf9 cells and subjected to a cold ERK1 assay (lane 2) or not (lane 1). The reactions were then subjected
to HDAC assays as shown in the bar graph. The phosphorylation of GST-HDAC6 was examined by anti-pSer/Thr Western blotting analysis. The amount
of HDAC6 was examined by anti-HDAC6 Western blotting analysis.
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Conversely, HDAC6 wild type and HDAC6(S1035A) exhibit
similar activity toward core histone H3 (Fig. 8A). To examine
whether HDAC6(S1035A) indeed mimics the nonphosphory-
lation status of HDAC6, knockdown of ERK1, ERK2, or both
was performed in 293T cells. As shown in Fig. 8B, depletion of
either ERK2 or ERK1 reduced the levels of HDAC6 Ser-1035
phosphorylation approximately to 50% comparedwith the con-
trol. Depletion of both ERK2 and ERK1 additively reduced the
phosphorylation levels of HDAC6 Ser-1035 to 28% compared
with the control. These results suggest that both ERK1 and
ERK2 are involved in HDAC6 Ser-1035 phosphorylation. Con-
sistent with Fig. 8A, knockdown of both ERK1 and ERK2 signif-
icantly increased acetylated -tubulin level compared with the
control, indicating that reduction of HDAC6 Ser-1035 phos-
FIGURE 8. S1035A mutant of HDAC6 displays decreased TDAC activity in vivo. A, HDAC6(S1035A) mutant exhibits decreased TDAC activity in vivo com-
pared with the wild type. CHO and H1299 cells were transfected with the indicated plasmids. After 36 h, cells were harvested and lysed. Western blotting (IB)
analyses were performed using the indicated antibodies. B, 293T cells were transiently transfected with the indicated shRNA to knock down ERK1 or/and ERK2.
shRNA vectors against ERK1 (TRCN0000006150; Sigma) and ERK2 (TRCN0000010040; Sigma) were used to knock down ERK1 and ERK2, respectively. pLKO.1-
puro empty vector was used as a control. These vectors were transfected individually or in combination as indicated into 293T cells for 24 h followed by the
same transfections for another 24 h prior to harvesting. Western blot analyses were then performed with the indicated antibodies. C, GST-HDAC6 protein was
purified from Sf9 cells. The proteins was either subjected to ERK1 kinase assay (lane 2) or not followed by TDAC assays as described under “Experimental
Procedures.” Ac-tubulin was detected by anti-Ac-tubulin Western blot analysis. The HDAC6 and pHDAC6 proteins were examined by Coomassie Blue staining.
The anti-pSer/Thr Western blot analysis was carried out to examine the phosphorylation of HDAC6.
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phorylation decreased its TDAC activity. Intriguingly, knock-
down of ERK2 did not alter the TDAC activity as did knock-
down of ERK1. It seems that ERK1- but not ERK2-mediated
phosphorylation regulates HDAC6 TDAC activity. In agree-
ment with these data, phosphorylation of HDAC6 by recombi-
nant ERK1 moderately increased HDAC6 TDAC activity (Fig.
8C). Furthermore, phosphorylation of HDAC6 in vivo with the
active Ras also increased HDAC6 TDAC activity (data not
shown). Overall, our data suggest that phosphorylation of
HDAC6 increases its TDAC activity.
Active c-Raf-mediated Cell Migration Is via HDAC6—To
investigate whether the Raf-MEK-ERK signaling cascade influ-
ences cellmigration viaHDAC6,we overexpressed active Raf in
wild type or HDAC6-null MEFs. As shown in Fig. 9A and B,
active Raf dramatically increased cell migration in wild type
MEFs compared with HDAC6-null MEFs in Boyden chamber
migration assays. Active Raf indeed elevated phospho-ERK lev-
els in both wild type and HDAC6-null MEFs (Fig. 9C, lanes 3
and 4). Interestingly, HDAC6-null MEFs possess higher phos-
pho-ERK levels compared with wild type (Fig. 9C, lane 2 versus
lane 1). This observation raised the possibility that HDAC6
plays a role in suppressing ERK activity. Further examination
will be warranted.
HDAC6-null MEFs Rescued by S1035A Displayed Decreased
Migration Potential Compared with Those Rescued by Wild
Type—Studies have implicated that HDAC6 promotes cell
migration through the deacetylation of its cytoplasmic sub-
strates -tubulin or cortactin (11, 13). As shown in Fig. 8A,
HDAC6 (S1035A) harbors lower TDAC activity compared
with wild type in vivo. We next determined whether
HDAC6(S1035A) would decrease cell migration compared
with wild type in a cell line model. As shown in Fig. 10,A and B,
HDAC6-null MEFs rescued by S1035A exhibited significantly
lower migration potential than those rescued by wild type. The
levels of HDAC6 protein expression in those rescued clones
were approximately equal (Fig. 10C). In agreementwith Fig. 8A,
the HDAC6(S1035A) rescued clone displayed lower TDAC
activity comparedwith thewild type rescued one, whereas both
clones exhibited similar HDAC activities for histone H3 (Fig.
10C). In conclusion, our results indicate that dephosphory-
lation of HDAC6 at the Ser-1035 site decreases its ability to
induce cell migration.
DISCUSSION
In this study, we have demonstrated that HDAC6 is a novel
ERK substrate.Wehave also identified Ser-1035 as amajor ERK
phosphorylation site in HDAC6.We have shown that HDAC6-
null MEFs rescued by nonphosphorylation mimicking mutant
displayed reduced migration potential compared with those
rescued by wild type. Overall, our results indicate that the
EGFR-Ras-Raf-MEK-ERK signaling pathway stimulates cell
migration via HDAC6 phosphorylation at Ser-1035 (Fig. 10D).
Apart from the Ser-1035 site, we have also identified Thr-
1031 as a phosphorylation site in HDAC6 (Figs. 1 and 2). How-
ever, as shown in Fig. 4C, HDAC6(S1035A) mutant could not
be phosphorylated efficiently by upstream kinases of ERK, sug-
FIGURE 9. Active Raf promotes cell migration via HDAC6. A, c-RAF-BXB plasmid was transfected into HDAC6 WT or KO MEFs. Cell migration assays were
performed as described under “Experimental Procedures.” The snapshots of the migratory cells are shown as indicated. B, the stained migratory cells were
de-stained in 2% SDS and then quantified at A560 nm. A bar graph was made after the quantification. C, anti-pERK, anti-ERK, anti-mHDAC6, and anti--tubulin
Western blot (IB) analyses were performed using the cell lines described in A and B. NS refers to not significant. ** indicates p  0.01.
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gesting that Ser-1035 is themajor site targeted by ERK and that
Thr-1031 may not be important for ERK-mediated phosphor-
ylation. Nevertheless, given the proximity of Thr-1031 and Ser-
1035, we cannot rule out the possibility that Thr-1031 phos-
phorylation/dephosphorylation influences HDAC6 function.
Future studies employing Thr-1031 phosphorylation or
dephosphorylation mimicking single mutant (T1031A and
T1031D) or Thr-1031 and Ser-1035 double mutants (T1031A/
S1035A and T1031D/S1035D) are warranted.
Early investigations have demonstrated that ERK1/2 is asso-
ciated with microtubules in the cytoplasm (24). Upon mitogen
stimulation ERK1/2 is translocated to the nucleus. As shown in
FIGURE 10. S1035A mutant of HDAC6 exerts decreased migration potential in MEFs. A, cell migration assays were carried out using HDAC6 KO MEFs cells
stably expressing empty vector, HA-HD6-F, or HA-HD6(S1035A)-F as described under “Experimental Procedures.” Snapshots of the migratory cells are shown
as indicated. B, the stained migratory cells were de-stained in 2% SDS then quantified at A560 nm. The bar graph represents the quantification. NS refers to not
significant. ** indicates p  0.01. C, Western blot (IB) analyses were performed using the indicated antibodies and the cell lines described in A. D, the working
model shows how the EGF-EGFR-Ras-Raf-MEK-ERK signaling cascade regulates cell migration via HDAC6.
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Fig. 6, HDAC6/ERK1/2 interaction was found in both nuclear
and cytoplasmic fraction of HeLa S3 cells. This observation
suggests that HDAC6may also be one of the nuclear substrates
of ERK1/2. Because EGF has pro-migratory function, we exam-
ined whether EGF affects HDAC6 phosphorylation. Our data
indicate that EGF increases HDAC6 Ser-1035 phosphorylation
(Fig. 5), suggesting that EGF induced cell migration via the
EGFR-Ras-Raf-MEK-ERK signaling cascade. A previous report
showed that EGFR phosphorylates HDAC6 at Tyr-570 and
decreases TDAC activity of HDAC6 (19). It is conceivable to
speculate that EGFR-mediated HDAC6 tyrosine phosphoryla-
tion increases -tubulin acetylation. Thus, it remains to be
determined how HDAC6 Ser-1035 and Tyr-570 in combina-
tion affect -tubulin acetylation and cell migration.
As shown in Fig. 8, HDAC6(S1035A) displayed lower TDAC
activity compared with the wild type in vivo. However, in an in
vitro TDAC assay, HDAC6(S1035A) exhibited higher activity
than the wild type (data not shown). This is very intriguing. It is
possible thatmore factors are associatedwithHDAC6 aswell as
its substrate, microtubules, in vivo than in vitro. More investi-
gations are certainly warranted. Although HDAC6 is also
located in the nucleus (Fig. 6A), we did not observe any differ-
ence among empty vector, HDAC6 wild type, or S1035A
mutant in terms of influencing core histone acetylation in vivo
(Figs. 8A and 10C). This could be because neither HDAC6 wild
type nor mutant interacts with core histones (data not shown).
We also examined the affinity of HDAC6 wild type or
HDAC6(S1035A) to tubulin by immunoprecipitation-Western
blot analysis (data not shown). Both HDAC6wild type and Ser-
1035mutant bind to tubulin, but we did not observe any differ-
ence in terms of binding between HDAC6 wild type or
HDAC6(S1035A) to-tubulin (data not shown). Therefore, the
mechanisms by which HDAC6(S1035A) displays reduced
TDAC activity compared with the wild type remain to be
explored.
Cortactin is an F-actin-binding protein and plays an essential
role in cell migration (13, 31, 32) and angiogenesis (32). It is also
an HDAC6 substrate (32). However, we did not observe any
differences in the deacetylation of cortactin between the
unphosphorylation and phosphorylation mimicking mutants
of HDAC6 at the Ser-1035 site (data not shown). This observa-
tion is consistent with the fact that ERK is associated with the
microtubules but not with actin or intermediate filaments (24).
This suggests that ERK-mediated HDAC6 phosphorylation
modulates tubulin-dependent cellmigration. Further studies in
our laboratory are aiming to identify novel proteins thatmay be
interacting with the phosphorylated form of HDAC6 to pro-
mote cell migration. Because HDAC6 interacts with ERK, it is
conceivable to speculate that HDAC6 could also regulate ERK.
In fact, we found that ERK activity is elevated in HDAC6-null
MEFs (Fig. 9C). It is possible that HDAC6 modulates ERK
acetylation, phosphorylation, and subsequently enzymatic
activity.
It is well documented thatHDAC6 is involved in transforma-
tion and tumorigenesis (33). Elevated expression of HDAC6
was observed in a panel of non-small cell lung cancer cell lines
comparedwith the nontransformed cells.4HDAC6overexpres-
sion leads to increased cell motility which is one of the key steps
in tumor metastasis (34–37). The EGFR-Ras-Raf-MEK-ERK
signaling pathway has attracted considerable attention as a tar-
get for anti-cancer therapy. It is plausible that the combination
of HDAC6-selective inhibitors and inhibitors targeting the
EGFR-Ras-Raf-MEK-ERK signaling cascade may represent an
effective strategy for cancer treatment.
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